NHEJ1-patients develop severe progressive lymphocytopenia and premature aging of hematopoietic stem cells (HSCs) at a young age. Here we show a patient with a homozygous-NHEJ1 mutation identified by whole exome-sequencing that developed severe pancytopenia and bone marrow aplasia correlating with the presence of short telomeres. The mutation resulted in a truncated protein. In an attempt to identify the mechanism behind the short telomere phenotype found in the NHEJ1-patient we downregulated NHEJ1 expression in 293T and CD34 þ cells. This downregulation resulted in reduced telomerase activity and decreased expression of several telomerase/shelterin genes. Interestingly, cell lines derived from two other NHEJ1-deficient patients with different mutations also showed increased p21 expression, inhibition in expression of several telomerase complex genes and shortened telomeres. Decrease in expression of telomerase/shelterin genes did not occur when we inhibited expression of other NHEJ genes mutated in SCID patients: DNA-PK, Artemis or LigaseIV. Because premature aging of HSCs is observed only in NHEJ1 patients, we propose that is the result of senescence induced by decreased expression of telomerase/shelterin genes that lead to an inhibition of telomerase activity. Previous reports failed to find this connection because of the use of patients cells immortalized by TERT expression or recombined telomeres by ALT pathway. In summary, defective regulation of telomere biology together with defective V(D)J recombination can negatively impact on
Introduction
DNA double-strand breaks (DSBs) are among the most toxic DNA lesions, and can be caused by cell-intrinsic sources such as replication errors or DNA-damaging agents naturally present in cells, including reactive oxygen species. DSBs can also result from exposure to a variety of extrinsic factors, including ionizing radiation (IR). Non-homologous end joining (NHEJ) is the major DSBs-solving pathway in mammalian cells and is active throughout the cell cycle. NHEJ processing works in a variety of DNA end configurations and ligates two DNA ends after DNA processing (1, 2) . DSBs are also generated as intermediates of physiological DNA rearrangement processes that take place during the development and maturation of the adaptive immune system V(D)J recombination and immunoglobulin [Ig] heavy chain class switch recombination (CSR) (3, 4) . Mutations in V(D)J recombination factors lead to (severe)combined immunodeficiency-(s)CID owing to the failure to carry out V(D)J recombination efficiently (5) (6) (7) . Around 20% of all T-and B-cell negative (T-B-)SCID patients carry a defect in V(D)J recombination (8) .
SCID patients carrying defects in Ligase IV, XLF/NHEJ1/ Cernunnos, Artemis or DNA dependent protein kinase (DNA-PK) activities have been identified. NHEJ deficient patients display radiosensitivity (9-13) along with immunodeficiency that results in a rare disorder with microcephaly, combined immunodeficiency, progressive lymphocytopenia and occasional myeloproliferative disease. In some cases, mutations in Artemis (14) and ligaseIV (15) have also been associated with the development of lymphomas and leukemias.
The profound T and B lymphocytopenia is very likely owing to the defect in V(D)J recombination. XLF-patients also develop premature aging of hematopoietic stem cells (HSCs) at a young age (16) (17) (18) . Defective XLF/NHEJ1 activity tested in vitro demonstrated its role in stimulating incompatible DNA end ligation by the XRCC4/DNA Ligase IV complex (19) (20) (21) . Surprisingly NHEJ1-deficient mice have no measurable defect in V(D)J recombination (18, 22) . In this animal model there is only a moderate decreased number of mature lymphocytes and NHEJ1 deficient pro-B-cell lines can support nearly normal levels of V(D)J recombination (23) . Recently a study had suggested that redundant functional properties of ATM and NHEJ1 in joining DNA breaks could explain this modest effect in lymphocyte development (24) .
Telomeres in vertebrates are repetitive TTAGGG DNA sequences located at the ends of chromosomes whose main function is to protect coding regions of DNA. Cancer cells and mammalian germline cells maintain the addition of TTAGGG repeats by telomerase activity. This activity corrects telomere shortening generated in every cell division and prevents senescence in these cells (25) (26) (27) (28) . Telomerase active complex is composed of the telomerase reverse transcriptase (TERT), telomerase RNA (TERC) and the protein dyskerin (29) . A complex of 6 telomere-binding proteins known as shelterin, protect telomeres from being recognized as broken chromosome ends (30) . A wide group of monogenic diseases termed telomeropathies are characterized by deficient telomere elongation and/or protection owing to mutations in genes either in the telomerase, in shelterin complexes, or in other telomeric factors rendering cells with deficient telomerase activity (31) , premature senescence and aging of different tissues.
Here we describe a patient with SCID and bone marrow aplasia correlating with short telomeres. By whole exome sequencing (WES) we identified a homozygous mutation in NHEJ1 gene (c.169C>T). We observed that downregulation of NHEJ1 expression in 293T and CD34
þ cells results in decreased telomerase activity and the inhibition in expression of several telomerase and shelterin genes. Two other cell lines derived from NHEJ1-patients, showed inhibition on expression of telomerase genes and short telomeres. This effect on telomerase and shelterin gene expression does not occur when we inhibited expression of DNA-PK, Artemis or Ligase IV. Our results suggest that besides immunodeficiency, premature aging in bone marrow cells of NHEJ1 patients may be the result of decreased expression of telomerase and shelterin genes and therefore decreased levels of telomerase activity leading to short telomeres. This observation should be taken into consideration for the treatment of these patients, owing to their fragile condition.
Results
Whole-exome sequencing and candidate variants in a SCID patient A 10-month-old boy (Patient 1) was first admitted for right upper lobe pneumonia and was diagnosed with immunodeficiency owing to severe hypogammaglobulinemia. The parents were second familial degree and there was no prior family history of immunodeficiency or hematological diseases. His prior medical history was only relevant for intrauterine growth retardation. He had low percentile weight and height (p3) by the time he first presented at the hospital. Intravenous immunoglobulins were prescribed, and he continued with this treatment every 3 weeks lifelong. At the age of four he presented with mild thrombocytopenia that worsened during the following months. Two years later, he developed mild pancytopenia, becoming transfusion dependent 1 year later. In parallel different immunodeficiency entities were ruled out by genetic studies. When he developed severe pancytopenia, studies confirmed the diagnosis of bone marrow aplasia. He underwent studies to rule out congenital bone marrow diseases, mainly Fanconi Anemia, but as part of these studies, telomere length was also measured to rule out Dyskeratosis congenita (DC) (32, 33) (Fig. 1A) . At this point we detected short telomeres that were under the first percentile, 7.4 kb (6 years) in contrast with both parents (8.6 kb) (42 and 43 years) (Fig. 1A) . We searched for the presence of mutations in different telomerase and shelterin related genes (DKC1, TERT, TERC, TINF2, Nola2, Nola3) but we could not find any mutated gene. He underwent hematopoietic transplantation from an unrelated donor 3 months after becoming transfusion dependent, but he died at the age of 8 (8 months after transplantation), owing to severe clinical complications and with no final diagnosis of his disease. We performed WES of the affected patient and the healthy mother. Eighty-five percent of target regions were observed with coverage >20Â. Variant calling was performed considering hypothesis of homozygosis (owing to the parents' consanguinity) and de novo heterozygosis (see Materials and Methods). Non-filtered 7 tandem duplications, 3 inversions and 202 indels and SNPs (splicing and stop gain) were obtained for the affected patient (124 in heterozygosis, de novo heterozygous and 88 in homozygosis) and fulfilled quality controls for downstream filtering. Twelve non-filtered variants fitted our assumption of function relation. Three of these variants (in genes FRG1, NHEJ1 and PRKDC) were annotated in codifying region and were prioritized (Table 1) . Both FRG1 and PRKDC variants were found in sequencing databases not associated with disease. In each case 200 cells were analyzed. ***P < 0.001.
From the selected variants we found a mutation at exon2 in NHEJ1 gene (c.169C>T, p.Arg57stop) in homozygosis that results in a truncated protein (Fig. 1B) . The mother was heterozygous for this mutation. Genetic studies in other members of this family showed that the father and most of the patient's uncles or aunts from both branches, and also his brother were heterozygous for this mutation (Fig. 1C ). When we studied the patients bone marrow expression of NHEJ1 we found that, very little or no protein was expressed (Fig. 1D) . Then, the final diagnosis was XLF/Cernunnos syndrome.
NHEJ1-disease associated mutations are very rare in population, and as far as we know only 12 NHEJ1-patients with germline inactivating mutations of NHEJ1 have been described (Table 2) (13, (34) (35) (36) (37) . All of the mutations already described resulted either in a truncated protein or a protein with very low activity. The patients presented a progressive and profound B and T lymphocytopenia, microcephaly and occasional myeloproliferative disease (16) (17) (18) (32) (33) (34) (35) . Even if the role of NHEJ1 in NHEJ and V(D)J recombination was thought to explain the disease, it has been shown that Nhej1-deficient mice have no measurable defect in V(D)J recombination (18) but recapitulate the age-dependent lymphocytopenia of patients (18, (32) (33) (34) (35) (36) . Recently NHEJ1 deficiency was reported to lead to accumulation of DNA damage in HSCs and premature aging (18, 36, 38) .
Inhibition of telomerase activity and decreased expression of telomerase and shelterin genes in cells expressing low levels of NHEJ1 gene Since Nhej1-deficient mice presented premature aging of HSCs (18) and in our patient we detected telomere shortening, we investigated if the lack of expression of NHEJ1 could have an impact on telomerase activity and telomere elongation. To that end we used two shRNAs for NHEJ1, shNHEJ1.2 and 1.3 to infect 293T cells that had high levels of telomerase activity. Expression of both shRNAs in contrast with the scramble vector resulted in reduced expression of NHEJ1. shNHEJ1.2 vector reduced the expression levels down to 40% while shNHEJ1.3 did only to 80% (Fig. 1E) . This difference in expression of NHEJ1 resulted in a poor growth of shNHEJ1.2 cells already at day 4 after transduction ( Fig. 1F) . Accordingly, only shNHEJ1.2 cells expressed high levels of p21 (CDKN1A) (Fig. 1E) . Growth of shNHEJ1.3 cells was equivalent to the scramble transduced cells, but was impaired after treatment with low doses of bleomycin (Fig. 1G) suggesting a high sensitivity to DNA damage even in the absence of evident growth defects (9-13). As our NHEJ1-patient did not express NHEJ1 protein, for the next functional studies we used the shNHEJ1.2 vector that resulted in low levels of NHEJ1 expression. This recreated the patients phenotype as NHEJ1 protein expression was not detected in his bone marrow. We assayed the presence of DNA damage by quantifying c-H2A.X-associated foci in shNHEJ1.2 transduced cells and found that shNHEJ1.2 cells have more foci per cell, indicative of DNA damage in basal conditions, as previously described in HSCs of Nhej1-deficient mice (18) (Fig. 1H and I) . In fact the levels of p53 protein and p-p53ser15 were increased in shNHEJ1.2 cells ( Fig. 2A) , but while p53 protein levels were increased 1.5-fold the ratio p-p53/p53 was only slightly higher ( Fig. 2A) .
Abnormally short telomeres found in our NHEJ1-patient, in the absence of mutations in telomerase complex associated genes might be a consequence of reduced telomerase activity. Indeed, we found that in 293T cells transduced with shNHEJ1.2 vector, telomerase activity was inhibited by 80% as compared with scramble cells (Fig. 2B ) already at 4 days after transduction. This inhibition in telomerase activity correlated with an inhibition in TERT protein expression ( Fig. 2A) . Inhibition in 
ho, homozigous; he, heterozigous.
telomerase activity induced by shNHEJ1.2, did not result in evident changes in telomere length ( Fig. 2C ) probably owing to the experimental conditions in which telomere length was measured in a short time after infection (4 days). Similar results have been described in a DKC1 genetically modified mouse model in which telomerase activity was inhibited and this was found also to inhibit cell growth without affecting telomere length (39, 40) . We also studied in shNHEJ1.2 293T cells, the expression levels of genes corresponding to proteins of the telomerase complex. We found an important decrease in expression of TERT (60%) (in agreement with the results presented in Fig. 2A ) and a milder inhibition of DKC1 (dyskerin) (20%) and NHP2 (40%) pression. Data were normalized to GAPDH levels and are shown as mean 6 SD of three independent experiments. Relative mRNA levels were normalized to scramble cell line expression.
expression (Fig. 2D) . We have also found inhibition on expression of genes from the shelterin complex or shelterinassociated factors: TERF1 (60%), TERF2 (30%) and TINF2 (75%) as well as CTC1 (40%) and RTEL1 (80%) (Fig. 2E) . Previous reports described that Nhej1-deficient mice showed premature aging of HSCs (18), therefore we transduced human CD34 þ cells with shNHEJ1.2 vector and analyzed the consequences on cell growth and telomerase activity. shNHEJ1.2/ CD34 þ transduced cells showed an inhibition of growth compared with scramble infected cells (Fig. 3A) , as previously observed in 293T cells (Fig. 1A) . These cells also showed increased expression of p21 (CDKN1A) 3-fold in relation with control cells (Fig. 3B ) and telomerase activity was reduced by 30% (Fig. 3C ). Expression of several telomerase genes was also inhibited, mainly TERT (40%), TERC (20%) (Fig. 3D) , and also the expression of some of the shelterin genes and shelterinassociated factors: TERF1 (40%), TERF2 (20%) and TINF2 (20%) and also CTC1 (25%) and RTEL (30%) (Fig. 3E) . These results indicated that the decrease in the expression levels of telomerase and shelterin genes was a reproducible consequence of the inhibition of NHEJ1 expression. This inhibition in gene expression very likely negatively impacted telomerase activity and therefore resulted in induced senescence.
Since expression of shNHEJ1.3 in 293T cells did not alter cell growth we treated them with bleomycin. We have found induction of p21 expression (Fig. 4A ), but not inhibition of telomerase activity (data not shown). In agreement with this data we have not found inhibition of the expression of telomerase or shelterin genes ( Fig. 4B and C) .
Two different NHEJ1-patient cell lines exhibited the same changes in expression of telomere genes observed in cell lines expressing low levels of NHEJ1/XLF gene We analyzed two NHEJ1-patient cell lines in Patient 2, who has been previously described (41) . Patient 2 is a girl born with low weight, growth retardation, microcephaly and severe combined immunodeficiency. Seven years after bone marrow transplantation, bone marrow counts and peripheral cell counts were found within the range of healthy age matched controls. The genotype revealed a homozygous non-sense mutation (c.C622T) in exon 5, which changes Arg codon at position 178 to a stop codon (p.R178*). Patient 3 is a boy presenting growth retardation, microcephaly (À4 SD). From early childhood he was suffering from recurrent pneumonias, bronchitis, low level of platelets and leukocytes. Hypogammaglobulinemia except for the IgM isotype, low levels of B cells (81/ml), high proportion of memory CD4 þ T cells (91.8% of CD4CD3 þ CD45RO þ cells) and no T cell proliferation. A homozygous p.Y167* mutation in XLF/ NHEJ1 was identified. The patient died of severe infection at 3yrs of age. Cell lines from these two patients showed induced expression of p53 and the ratio p-p53/p53 was only slightly higher ( Fig. 5A) as observed in shNHEJ1.2 293T cells (Fig. 2) . This increased expression of p53 resulted in both NHEJ1 mutated cell lines in increased expression of p21 (CDKN1A) in relation with control cells (Fig. 5B ).
We performed telomeric repeat amplification protocol (TRAP) assays and found that telomerase activity for both patient cells was undetectable. Interestingly we found a significant inhibition in expression of the telomerase complex genes TERT (60%), TERC (40%), Dyskerin (50%), NHP2 (20%) and NOP10 (30%) (Fig. 5C ). When we studied expression of shelterin genes we found a significant inhibition in expression of TERF2 and TINF2 (Fig. 5D ). This inhibition in the expression of telomerase components should be responsible for the shortened telomeres found in both patients' cells when compared with controls of the same age (Fig. 5E) as also determined for Patient 1.
Inhibiting expression of DNA-PK (PRKDC), artemis (DCLRE1C) and ligase IV (LigIV) does not modify telomerase activity or expression of telomerase genes Since XLF/NHEJ1 stimulation is involved in the DNA ligation by the XRCC4/DNA Ligase IV complex (19) (20) (21) , the last step in the repair process of DSB, we investigated if inhibition in expression of other genes of this repair pathway involved in SCID phenotype, would affect telomerase activity. We inhibited the expression of DNA-PK (PRKDC), Artemis (DCLRE1C) and Ligase IV in 293T cells. Lentiviral vectors expressing shRNAs specific for each gene and as a control a scramble vector were used. We found that inhibiting the expression of any of the three genes did not induce significantly the expression of p21 (CDKN1A) (Fig. 6A) or decrease the expression of TERT or TERC, but all three induced a very mild inhibition in expression of DKC1 (Fig. 6B) , but telomerase activity was not modified after inhibition in the expression of DNA-PK, Artemis or Ligase IV (Fig. 6C ).
Discussion
We describe here a novel connection between dysfunction of the NHEJ pathway and telomere biology regulation that may have an impact in SCID-patient diagnosis and treatment. We have found that a mutation at exon2 in NHEJ1 gene (c.169C>T, p.Arg57stop) in homozygosis resulted in a truncated protein in a SCID patient (Patient 1) showed the absence of expression or NHEJ1/XLF protein in the bone marrow. The patient also presented short telomeres by his age but, surprisingly, we did not detect mutations in any of the telomerase-related genes. We have also shown that downregulation in NHEJ1 by NHEJ1-shRNA expression in two cell models including 293T and CD34 þ cells resulted in the inhibition in telomerase activity after a short time of expression. This decrease in telomerase activity may be justified by inhibition in the expression of some of both, the telomere biology related genes including TERT, NHP2, TERF1, TERF2, TINF2, CTC1 and RTEL1. Mutations that resulted in deficient activity of these proteins are associated with inhibition in telomerase activity and/or telomere loss (31) . The observed stimulation of CDKN1A expression that could be related to growth inhibition observed in cells expressing low levels of NHEJ1. Interestingly, the shelterin component TRF2 (the TERF2 gene product) controls ATM activity, that phosphorylates and thereby activates p53 (42) , establishing the TRF2-ATM-p53 pathway as a downstream effector pathway of the DNA damage response (DDR) initiated at uncapped telomeres. Accordingly, Fujita et al. (43, 44) have described that p53 activation in response to telomere shortening can induce degradation or TRF2 through the TRF2-ATM-p53 negative feedback loop that further links increased p53 activation to telomere shortening.
In this manuscript, we have used two NHEJ1-patient cell lines (Patients 2 and 3) that have not been previously immortalized and both showed changes in expression of p53, CDKN1A, inhibition of expression of telomerase and telomere biology genes and finally telomere shortening in comparison to their age-matched healthy controls. The data correlated with the results obtained from Patient 1, and with NHEJ1-shRNA expression in 293T and CD34 þ cells. This data strongly support that the inhibition in NHEJ1 activity may result in the inhibition in telomerase activity and telomere shortening. Previous data indicated that downregulation of NHEJ1 expression in U2OS cells (45) , induced radiosensitivity and defective DNA repair. Other reports (10, 13, 45) have used NHEJ1-patient cells and also reported radiosensitivity and defective DNA repair. None of these reports have found impaired growth of NHEJ1/XLF deficient cells or changes in expression of telomerase genes. An explanation for the differences observed with our work might be the use of TERT immortalized patient cells in these reports.
Other manuscripts used U2OS cells that are known to maintain telomere length by the ALT pathway independently of telomerase activity (46) . Therefore, either using cells expressing TERT from a plasmid vector or using those that do not require telomerase activity to support cell division would be difficult to detect alterations in cell growth in cells with inhibited or altered expression of NHEJ1. These differences in methodology with respect to previous reports, may explain our results regarding telomerase gene expression. The high basal levels of DNA damage observed in 293T shNHEJ1.2 expressing cells may result from the deprotection or uncapping of telomeres owing to the low levels of expression of shelterin and telomerase complex genes. We have also found that 293T cells expressing the shNHEJ1.3 virus (a milder Relative mRNA levels were normalized to scramble cell line expression. (E) Quantification of TERF1, TERF2, TERF2IP, TINF2, CTC1 and RTEL1 mRNA levels in CD34 þ cells by RT.qPCR after 4 days of scramble or shNHEJ1.2 expression. Data were normalized to GAPDH levels and are shown as mean 6 SD of three independent experiments.
Relative mRNA levels were normalized to scramble cell line expression.
inhibitor of NHEJ1 expression) are sensitive to treatment with bleomycin but they display normal growth kinetics. 293T cells expressing shNHEJ1.2 virus that strongly inhibited NHEJ1 expression showed increased cH2AX foci formation even in basal conditions, in the absence of bleomycin, suggesting high basal damage induced by the low expression level of NHEJ1. This increase in DNA damage correlates with the decrease in expression of shelterin genes TRF1 and TRF2 and might be owing to deprotection of telomeres as previously reported (30) . Patients with germline mutations in NHEJ1 develop progressive lymphocytopenia, microcephaly, and occasionally myeloproliferative disease. NHEJ1-deficient mice have reduced lymphocyte numbers but few defects in V(D)J recombination (18, 22) are present. Consistently, NHEJ1-deficient lymphocytes perform chromosomal V(D)J recombination normally, but severe defects in extrachromosomal V(D)J recombination in NHEJ1-deficient murine embryonic stem cells. These results suggest that one or more alternative repair pathway(s) might exist in developing lymphocytes to compensate for the loss of NHEJ1 during V(D)J recombination in mice. Recent work points to ATM as a compensatory factor for this effect (24) .
In thymocytes of NHEJ1/XLF null mice there is an important activation in the expression of p53-dependent genes involved in apoptosis, as PUMA, P21, BID and BAX. There is a reversion on the expression levels of these genes in NHEJ1 À/À P53 À/À double KO mice. Therefore in this NHEJ1-KO model there is a chronic activation of the DDR and subsequent p53-driven upregulation of proapoptotic factors, leading to decreased thymocyte viability. In our models of human cells transfected with shNHEJ1.2 virus there is a strong activation of the DDR, p53 activation followed by induction of the expression of p21.
We propose that the difference in the type of p53-dependent genes induced in human (293T or CD34 þ ) cells, inducing senescence (p21), and in NHEJ1/XLF null mouse model that involves apoptosis may be owing to the low telomerase activity and short telomeres present in human cells versus long telomeres in mouse cells. In human cells telomerase inhibition results in senescence induction (31) probably by telomere deprotection.
Our experiments also show that inhibition in the expression of other genes that have been found mutated in SCID patients such as Artemis, DNAPK or Ligase IV do not impact telomere gene regulation or p21 expression induction. Although mutations in these genes induce radiosensitivity, DNA damage is not induced in basal conditions (17) . This situation is similar to the results that we obtained expressing shNHEJ1.3 virus in 293T cells that only induce a small reduction in NHEJ1 expression levels and radiosensitivity but not basal DNA damage.
Interestingly double NHEJ1 À/À p53 À/À mice do not develop B cell lymphomas, in contrast with other NHEJ deficiency situations. XLF deficiency in mice leads to the accumulation of DNA damage in thymocytes (22) and in HSCs (18) and induces premature aging of HSCs, evidenced by reduced trilineage reconstitution, self-renewal, and myeloid bias at young ages. Therefore there is an important reduction in cell renewal that may compensate and impair cancer predisposition in NHEJ1 deficient mice. The findings presented here may explain why our Patient 1, with germline mutation in NHEJ1, developed progressive lymphocytopenia owing to inhibition of telomerase activity and telomere shortening. We also observed in shNHEJ1.2 expressing cells increased DNA damage, expression of p53 and p21 and decreased growth that agrees with the clinical manifestations observed in NHEJ1-patients and also the premature aging of HSCs observed in Nhej1-deficient mouse models (18, (32) (33) (34) (35) (36) . Defective regulation of telomere biology together with defective V(D)J recombination can negatively impact the evolution of the disease in these patients. The involvement of p53 or p21 expression in this process remains to be established (Fig. 7) . It also stresses the relevance of telomere biology regulation in these patients. Identification of telomere shortening is important since it may open new therapeutic interventions for these patients by treatments aimed to recover the expression of telomerase genes. 
Materials and Methods

Patients
A 6-year-old boy with a history of immunodeficiency was selected for WES together with his mother. Blood samples from other family members were also used for Sanger cosegregation. Peripheral blood mononuclear cells (PBMCs) were isolated from each blood sample (obtained in EDTA tubes) with Ficoll-PAGE and were incubated overnight with lysis buffer (150 mM NaCl, 50 mM EDTA, 20mM Tris-HCl pH 7.6 and 1% Na-Lauroyl sarcosine) and proteinase K (100 mg/ml) at 56 C. Genomic DNA was extracted using phenol:chloroform:isoamilic alcohol (25:24:1) and chloroform, precipitated with ethanol and resuspended in TE buffer. TeloTAGGG Telomere Length Assay (Roche) was used to determine the mean telomeric length for each patient and their parents using 1.5 mg of genomic DNA. Telomere length values of control population samples from different ages were used to calculate the relative telomere length at similar ages as previously described (32) . In all cases an informed consent was obtained.
Whole exome sequencing
Exomes from affected patient and the healthy mother were fully captured and enriched using the 71 Mb Agilent's Sure Select Whole Exon capture kit (Agilent Technologies). Sequencing was achieved using a Solexa platform (Illumina Genome Analyzer II) using two lanes per sample and generating 78-bp long 'Paired end' reads. The quality controls of the reads and the alignment with a genome of reference were based in a homemade bioinformatic pipeline; coverage metrics, target enrichment, PCR duplicates, overrepresented sequences and low quality reads considering per base and per sequence quality scores (Fastqc >30) were evaluated with a modular set of custom scripts previously described in (47) . BWA files of short reads were mapped against a genome of reference (GRCh37/hg19) with Novoalign version 2.06.09 (available at www.novocraft.com). Variant calling was performed for those variants in Exome of the patient affecting the frame based on deleteriousness criteria. SNPs and INDELs affecting frameshift were selected using Picard-tools [available at http://broadinstitute.github.io/picard/ Samtools (48)]. 7 HapMap cell lines (HapMap cell lines Na11881, Na12144, Na12750, Na12761, Na12763, Na12813 and Na12892; Coriell Cell Repositories) (47) were used as a filtering control to discard described variants and GRCh37/hg19 to rule out variants with a MAF <0.03 for recessive and <0.01 for dominant inheritance. The overall sample coverage distribution along targeted regions was evaluated at this point. Variants were filtered considering depth score (DS), which was calculated as a ratio of the read depth between the variant and reference alleles in a percentage format. DS between 20 and 210 and DS <140 were used for quality filter of SNPs and INDELs, respectively. Identified variants were annotated using Annovar (49) and Ensembl database (release 64) (50) 5. Allele frequencies spanning from 0.2 to 0.8 and over 0.8 were considered for recessive and dominant hypothesis, respectively. Homozygous variants in the affected patient were only considered when a healthy sequenced parent had a frequency below 0.8. Heterozygous variants in the affected patient were included as putatively de novo mutations when a healthy sequenced parent had a frequency below 0.2. Non-filtered variants were selected considering they were annotated in genes with DNA-stability or telomere biology function relation. Candidate variants were validated by Sanger sequencing. Primers are shown in Supplementary Material, Table S1 . Validated variants in codifying regions were prioritized. 
Cell lines and primary cells
Real-time quantitative PCR
Total cellular RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. For reverse transcription reactions (RT), 1 mg of the purified RNA was reverse transcribed with 0.02 mg of random hexamers, 0.5 mM of dNTPs (Sigma) and RT buffer 1Â for 5 min at 70 C and later 10 U/ml of MMLV (Promega, USA) and 1 U/ml of 
Taqman probes
The Taqman probes used were: 
Telomere length analysis
TeloTAGGG, Telomere Length Assay (Roche) was used to determine the mean telomeric length for each patient and their parents using 1.5 lg of genomic DNA, and the results were compared with a control population at similar ages (51) . Alternatively, the relative telomere length (TL) was assessed by a quantitative Polymerase Chain Reaction (qPCR) method previously described (32) that determines the ratio of telomere (T) repeat copy number to single-copy (S) gene (36B4) copy number (T/S ratio) in experimental samples as compared with a reference DNA sample.
Telomere PCRs and 36B4 PCRs were performed in separate wells using the following primers: TelF reference DNA (genomic DNA from human cell line MCF-7) was included in each run to allow the relative quantification of the samples. The telomere length of MCF-7 DNA (determined by Southern blot analysis) was used to convert T/S ratio in equivalent kilobases (kb). One T/S ratio unit corresponds to 4.8 kb.
Each sample was run in triplicates. qPCRs were carried out on a Eco Real-Time PCR System (Illumina).
TRAP assay
Telomerase activity was determined under recommended standard conditions of the TRAPEZE V R Telomerase Detection S7700 Kit (Millipore) for TRAP using radioisotopic detection. Telomerase activity was determined in each sample using 0.5, 0.25 and 0.125 mg of protein extract and normalized with the internal control included in the assay (52) .
Sanger sequencing of genomic DNA fied product was purified with exosap (USB-Affymetrix) and direct bidirectional Sanger sequencing was performed using an ABI 3700 automated sequencer and BigDye terminator cycle sequencing reagents (Applied Biosystems).
Immunohistochemistry studies
NHEJ1 expression was determined in biopsies from bone marrow, colon and skin from the patient and control by using a specific antibody recognizing the full length NHEJ1 (anti-XLF/NHEJ1 1F3, ab119375; Abcam). Briefly formalin-fixed paraffin-embedded sections from the indicated patient tissues and control tissues were used for immunohistochemistry analysis. Antigens were retrieved with the Dako buffer citrate pH 9 in a DAKO PT Link for 20-40 min (Dako, Glostrup, Germany). Sections were stained using an automated system DAKO Austostainer. Immunohistochemistry was performed using the Dako Envision Flex kit. Immune reactions were developed with diaminobenzidine and sections were counterstained with Harris' hematoxylin.
Western blot analysis and immunofluorescence
Antibodies
The source of antibodies was as follows: phospho-Histone H2A.X Ser139 (2577; Cell Signaling), p53 (9282; Cell signaling), p53ser15 (9284; Cell signaling), XLF/NHEJ1 1F3 (Abcam, ab119375), a-tubulin (T9026; Sigma-Aldrich) and TERT (H231, Santa Cruz). Fluorescent antibodies were conjugated with Alexa fluor 647 (A21236, Molecular Probes, Carlsbad, CA, USA).
Western blot
Whole cell extracts from 293T, CD34 þ , Patient 1 and P2 cells were prepared using a lysis buffer (25 mM HEPES pH 7.5, 0.3 mM NaCl, 1.5 mM MgCl 2, 0.2 mM EDTA, 20 mM b-glycerophosphate and 0.1% Triton X-100) and a protease inhibitor cocktail (0.5 mM ABSF, 2 lg/ml Leupeptine, 2 lg/ml aprotinin, 0.5 mM DTT and 0.1 mM Na 3 VO 4 ). Lysates were centrifuged and protein concentration was measured by using the Bio-Rad protein assay (500-0006; Bio-Rad). Twenty micrograms of protein extract were resolved on SDS-polyacrilamide and electroblotted to Immobilon P membranes (Millipore). Western blot analysis was conducted by using ECL reagent (Santa Cruz Biotechnology). Protein localization was carried out by fluorescence microscopy. For this purpose, cells were grown on coverslips, infected and fixed in 3.7% formaldehyde solution (47608; Fluka, Sigma, St. Louis, MO, USA) at room temperature for 15 min. After washing with 1Â PBS, cells were permeabilized with 0.2% Triton X-100 in PBS and blocked with 10% horse serum before overnight incubation with c-H2A.X antibody. Finally, cells were washed and incubated with secondary antibodies coupled to fluorescent dye (alexa fluor 647). Imaging was carried out at room temperature in Vectashield, mounting medium for fluorescence (Vector Laboratories, Inc.). Image acquisition was carried out with a Confocal Espectral Leica TCS SP5 microscope, using a HCX PL APO Lambda blue 63X1.40 OIL UV, zoom 2.3 lens, and processed with ImageJ software.
Statistical analysis
For the statistical analysis of the results, the mean was taken as the measurement of the main tendency, while standard deviation was taken as the dispersion measurement. Student's t test was performed. The significance has been considered at *P < 0.05, **P < 0.01 and ***P < 0.001. GraphPad Software v5.0 was used for statistical analysis and graphic representations.
